Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
NY Genome Center
The $125 million New York Genome Center (NYGC), set to start operations in the spring, unites 11 academic medical centers, with the shared goal of developing one of North America’s largest genomics facilities. Another goal for the genome center: close the longstanding gap in grant financing and infrastructure between New York and the nation’s top bioclusters, led by the San Francisco and Boston/Cambridge regions. “In many ways, New York missed the genomic era, and I don’t think anyone really realized how deep the problem was until they stopped to look at it,” Nancy J. Kelley, founding executive director of NYGC, told GEN. The center has raised about $100 million so far and has won support from corporate partners that include Roche and Illumina. What role do you see the NYGC playing in the growth of the city’s biotech cluster?